ARMP

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2009, for Targeted Genetics Corporation (Note: The input metadata referenced "Armata Pharmaceuticals," but the filing text explicitly identifies the registrant as Targeted Genetics Corporation). The company is a biotechnology firm focused on developing gene therapeutics. During the period, the company significantly reduced its workforce from 68 to approximately 13 employees and sold key manufacturing assets to Genzyme Corporation to extend its cash runway.

Key Financial Metrics

Notes: The net income for the nine-month period was significantly driven by a non-cash reversal of accrued restructure charges. Operating cash flow for the nine months ended September 30, 2009, was a net use of $1.49 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 113% for the three months ended September 30, 2009, compared to the same period in 2008, primarily due to $3.03 million in revenue recognized from the Genzyme asset sale agreement.
• Profitability Shift: The company reported a net income of $0.67 million for the quarter, a reversal from a net loss of $2.66 million in the prior year quarter. This was largely due to a $6.42 million credit from the reversal of previously accrued restructure charges related to the termination of the Bothell facility lease.
• Expense Reduction: Research and development expenses decreased 53% for the quarter and 51% for the nine-month period compared to 2008, reflecting workforce reductions and the completion of certain manufacturing campaigns.
• Asset Liquidation: Cash and cash equivalents decreased from $5.22 million at year-end 2008 to $3.97 million at September 30, 2009, despite the $3.5 million upfront payment from Genzyme, due to operating cash burn.

Outlook, Risks, and Management Commentary

• Cash Horizon: Management believes current resources, including the $3.5 million received from Genzyme and up to $3.5 million in potential milestone payments, are sufficient to fund operations through 2010.
• Strategic Pivot: The company has discontinued its ALS program and is evaluating its Huntington's Disease program. It is focusing on its lead product candidate for Leber's congenital amaurosis (LCA) and supporting partner relationships (Celladon, Genzyme, Amsterdam Molecular Therapeutics).
• Nasdaq Listing Status: The company received a conditional exception from Nasdaq to remain listed. It must demonstrate shareholders' equity of at least $2.5 million by January 19, 2010, and a closing bid price of $1.00 for 10 consecutive days by February 8, 2010. Failure to comply will result in delisting.
• Legal Proceedings: A lawsuit filed by the spouse of a patient who died during a 2007 clinical trial (tgAAC94) seeks unspecified damages. The FDA and independent boards previously determined the death was not caused by the product.
• Risk Factors: Significant risks include the inability to raise additional capital post-2010, the unproven nature of gene therapy, potential delisting from Nasdaq, and reliance on third-party collaborators for funding and development.

Investor Verification Checklist

• Verify the status of the Genzyme Agreement milestone payments and the likelihood of receiving the remaining $3.5 million.
• Confirm compliance with Nasdaq listing requirements (shareholders' equity and bid price) by the January and February 2010 deadlines.
• Assess the sufficiency of the $3.97 million cash balance to fund operations through 2010 given the reduced workforce and ongoing R&D costs.
• Review the progress of the LCA clinical trial and the potential for future funding requirements beyond the current cash horizon.
• Monitor the lawsuit regarding the 2007 clinical trial adverse event for any updates on liability or settlement.